Publication:
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.

dc.contributor.authorGayoso, J
dc.contributor.authorBalsalobre, P
dc.contributor.authorPascual, M J
dc.contributor.authorCastilla-Llorente, C
dc.contributor.authorLopez-Corral, L
dc.contributor.authorKwon, M
dc.contributor.authorSerrano, D
dc.contributor.authorPiñana, J L
dc.contributor.authorHerrera, P
dc.contributor.authorFerra, C
dc.contributor.authorPascual, C
dc.contributor.authorHeras, I
dc.contributor.authorMontesinos, P
dc.contributor.authorZabalza, A
dc.contributor.authorBento, L
dc.contributor.authorFiguera, A
dc.contributor.authorBuño, I
dc.contributor.authorDiez-Martin, J L
dc.contributor.funderMinistry of Economy and Competitiveness ISCIII-FIS
dc.contributor.funderERDF (FEDER) Funds from the European Commission, ‘A way of making Europe
dc.contributor.funderAsociación Española Contra el Cáncer (AECC)
dc.contributor.funderFundación Mutua Madrileña (FMM)
dc.date.accessioned2023-01-25T08:32:23Z
dc.date.available2023-01-25T08:32:23Z
dc.date.issued2016-05-09
dc.description.abstractRelapsed or refractory Hodgkin lymphoma (advanced HL) still remains a therapeutic challenge. Recently, unmanipulated haploidentical related donor transplant with reduced conditioning regimen (HAPLO-RIC) and post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has became a promising rescue strategy potentially available to almost every patient. This paper reports our multicenter experience using an IV busulfan-based HAPLO-RIC regimen and PT-Cy in the treatment of 43 patients with advanced HL. Engraftment occurred in 42 patients (97.5%), with a median time to neutrophil and platelet recovery of 18 and 26 days. Cumulative incidences of grades II-IV acute GvHD and chronic GvHD were 39% and 19%, respectively. With a median follow-up of 25.5 months for survivors, 27 patients are alive, with 22 of them disease free. Cumulative incidences of 1-year non-relapse mortality and relapse at 2 years were 21% and 24%, respectively. The estimated 2-year event-free survival (EFS) and overall survival (OS) were 48% and 58%, respectively. CR prior to HAPLO-RIC correlated with better EFS (78.5% vs 33.5%; P=0.015) and OS (86% vs 46%; P=0.044). Our findings further confirm prior reports using HAPLO-RIC in advanced HL in a multicenter approach employing an IV busulfan-based conditioning regimen.
dc.description.sponsorshipThis work was partially supported by the Ministry of Economy and Competitiveness ISCIII-FIS grants PI11/00708, PI14/01731 and RD12/0036/0061, co-financed by ERDF (FEDER) Funds from the European Commission, ‘A way of making Europe’, as well as grants from Asociación Española Contra el Cáncer (AECC) and Fundación Mutua Madrileña (FMM).
dc.description.versionSi
dc.identifier.citationGayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312
dc.identifier.doi10.1038/bmt.2016.115
dc.identifier.essn1476-5365
dc.identifier.pmid27159177
dc.identifier.urihttp://hdl.handle.net/10668/10067
dc.issue.number10
dc.journal.titleBone marrow transplantation
dc.journal.titleabbreviationBone Marrow Transplant
dc.language.isoen
dc.organizationHospital Universitario Regional de Málaga
dc.page.number1307-1312
dc.provenanceRealizada la curación de contenido 13/03/2025
dc.publisherNature Publishing Group
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.relation.projectIDPI11/00708
dc.relation.projectIDPI14/01731
dc.relation.projectIDRD12/0036/0061
dc.relation.publisherversionhttps://doi.org/10.1038/bmt.2016.115
dc.rights.accessRightsRestricted Access
dc.subjectSpain
dc.subjectSurvival Analysis
dc.subjectTransplantation Conditioning
dc.subjectTransplantation, Haploidentical
dc.subjectYoung Adult
dc.subject.decsBusulfano
dc.subject.decsTrasplantes
dc.subject.decsInforme de Investigación
dc.subject.decsNeutrófilos
dc.subject.decsPlaquetas
dc.subject.decsCiclofosfamida
dc.subject.decsEnfermedad de Hodgkin
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBusulfan
dc.subject.meshCyclophosphamide
dc.subject.meshFemale
dc.subject.meshGraft vs Host Disease
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshSalvage Therapy
dc.titleBusulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
dc.typeresearch article
dc.volume.number51
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format